The authors also concluded that increments in serum T levels do not cause disease progression, that PSA increase after TRT does not necessarily translate into clinical or symptomatic disease progression, and that TRT improves symptoms of hypogonadism and can be continued for years. This evidence concerns the gene KLK3 and hypogonadism.